Search
The Zayed Centre for Research into Rare Disease in Children at Great Ormond Street Hospital (GOSH) in London has already been at the cutting edge of new technologies since it opened in 2019
Aofie Regan, Director of Charitable Programmes and Impact at GOSH's Children's Charity, describes the research that happens there, which is transparently on display for the public to see from the street. In addition to do work directly there that might not be driven forward on its own, they also recently initiated a clinical trials funding programme.
2 days ago
BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it
He says he sees generalist investors coming back to biotech for the first time in a while, which have been benefitting the IPO market and other areas of the sector. Plus, the areas he is focused on today and what it take to be a successful IPO candidate. Coverage brought to you by
Jun 22
EHA 2026: H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor previews key EHA data from Legend and Incyte, and shares catalysts he is watching for after the conference
He discusses in vivo CAR-T data from Legend, and how Incyte is planning for the loss of exclusivity on Jakafi. Plus, his take on last week's summit data, and watching out for future catalysts from Ionis and Tyra.
Jun 11
At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe
He believes that GLPs will always be the backbone of weight loss therapies and points out that they are the only weight loss medicines that have shown a cardiovascular benefit. Plus, why he thinks entrepreneurs in Europe should take a nod from other areas and be more nimble and take more risks in the future.
Jun 7
At Nucleate UK's The Forum, early stage biotech investor Nirmesh Patel of Amino Collective says there is currently a bifurcation in fundraising between biotech co's with an AI angle and those without
He says the mood overall in biotech is dramatically better than it has been during the previous 2-3 years, and he is unsure about whether the AI factor will continue to attract investors like generalists who have been revisiting the sector.
Jun 4
At Nucleate UK's The Forum 2026, Oxford Nanopore Founder Gordon Sanghera shares his take on the next generation of biotech leaders and the innovation ecosystem in the UK
He describes how new technologies will revolutionize biotech, and his hope that more UK companies grow for the long-term rather than being sold to foreign multi-nationals.
Jun 4
At today's grand opening celebration of THE HIVE, a premier new oncology research incubator building in Paris next to Institut Gustave Roussy, the CEO of its builder, Kadans, discusses the facility
Steijn Ribbens describes the facility and how it is built to accelerate oncology research and the biotech sector in France, and how Kadans is working to build out biotech in this way throughout Europe.
Jun 4
Today in Paris is the grand opening celebration of THE HIVE, a cornerstone building within proximity of Institut Gustave Roussy meant to provide a place to incubate and translate science to industry
Paris Saclay Cancer Cluster President Eric Vivier describes the building, the goal of ramping biotech innovation for oncology in France, and what areas of science will be a focus.
Jun 4
During the grand opening celebration of THE HIVE, a new oncology incubator building in Paris, Paris Saclay Cancer Cluster CEO Benjamin Garel describes efforts to make France globally competitive
He discusses the importance of this new building and the value it brings by congregating France's innovators together. Plus the elements that Paris Saclay Cancer Cluster looks for when supporting a company. It all starts with great science.
Jun 3
At the opening celebration of THE HIVE, a new oncology biotech incubator in Paris, Sanofi's Global Head of External Innovation describes the idea behind creating the Paris Saclay Cancer Cluster
Jacques Volckmann describes the thought that went into creating PSCC, and why he is excited for the opening of THE HIVE, which Sanofi will have a presence in. Plus, what interests him in oncology today.
Jun 3
ASCO 2026: Yale Cancer Center's Roy Herbst, recognized as one of the foremost leaders in lung and head & neck cancer research, shares his take on what's in focus at this year's ASCO Annual Meeting
He comments on the progress of PD-1 x VEGF, a closely watched RET inhibitor, and how the field is doing in head & neck cancer lately. Plus, the presentation that everyone is waiting for in pancreatic cancer.
May 29
RBC Global Healthcare Conference: Global Head of Healthcare Investment Banking Darren Campili discusses the environment for fundraising, IPOs, and M&A
He shares his take on the ability for mid and small cap biotech companies to raise money and go public, which he describes as being very catalyst dependent.
May 19
RBC Global Healthcare Conference: US Large Cap Pharma Analyst Trung Huynh shares his take on the obesity market and rates Pfizer's last two major acquisitions
He discusses Lilly (his top pick) and the launch of Foundayo, and shares how he thinks about Pfizer's last two large acquisitions for Metsera and Seagen.
May 19
RBC Healthcare Conference: RBC Senior Analyst Luca Issi shares his take on biotech and comments on key companies he covers that have been in the news
He discusses Ionis, Arrowhead, REGENXBIO, uniQure, and more.
May 19
ASGCT 2026: Genetic Medicines Expert TJ Cradick highlights what are the key topics heading into the start of ASGCT
He highlights key issues around capsids and immunogenicity, in vivo engineering, using cell therapies for autoimmune, and, of course, how AI is affecting this science. Coverage brought to you by
May 12
Wharton Biotech Conference: MatchPlay CEO and Neuvation Ventures Managing Partner Mahesh Narayanan shares advice investing in people and maximizing talent in biotech
He shares advice for what areas of science PhDs might pursue in industry, how to success (get stuff done) and validating science.
May 11
Friedrich von Bohlen, Co-Founder & CEO of the data science company Molecular Health, has been at the forefront of biotech in Germany since the 1990's. He describes his work and thoughts on the sector.
He highlights the work of building Molecular Health's databases since it was founded in 2004, and how the company helps pharma and biotech companies make more informed and efficient drug development decisions. Plus, his thoughts on the state of biotech innovation in Germany and how he thinks the environment can be improved.
May 1
From Germany: Kevin Jahnke is leading research at the Max Planck Institute for Medical Research to better understand cell membranes and lipids. This type of work is vital for improving drug delivery
He introduces us to the Max Planck Society and his work. We discuss different types of cell membranes, how to get lipid nanoparticles to places in the body other than the liver, payload sizes, and where he hopes his work will ultimately lead.
Apr 29
From Germany: Heidelberg University's Dean of the Faculty of Medicine, Dr. Michael Boutros, describes the areas of biomedical research that the university is at the forefront of
Having been for years the home of important and well known medicines like Pluvicto, he describes some of the cutting edge research happening in Heidelberg today, both in oncology and non-oncology areas. Plus, a brief discussion of a personal passion of his, the Wnt/β-catenin pathway, and a new collaboration between Heidelberg and Harvard.
Apr 28
From Heidelberg: bioRN Executive Director Julia Schaft describes the world class science happening in the Rhine-Neckar region today and how they are trying to catalyze more biotech companies out of it
She describes the universities, research intitutes, and industry that exists here, and how bioRN is working to connect them together and grow the biotech sector in the region. Plus, comments on the entrepreneurial environment, VC landscape, and more.
Apr 28
.png){kind=logo}